FTC Sends Refunds to Consumers Who Bought Deceptively Marketed ‘Miracle’ Pain Cure for Older Adults

Manatt, Phelps & Phillips, LLP
Contact

Manatt, Phelps & Phillips, LLP

In another case, the Federal Trade Commission (FTC) announced that it is sending checks totaling more than $76,000 to consumers who bought Isoprex, a purported “miracle” pain supplement marketed to older Americans nationwide.

According to the FTC’s April 2020 complaint, Renaissance Health Publishing, LLC, and its owner, James DiGeorgia, advertised and sold Isoprex using both direct mail brochures and websites. Isoprex is a pill consisting primarily of a combination of various herbs and spices, which the defendants claimed could provide effective relief for older adults suffering from muscle and joint pain, headaches, arthritis, joint inflammation, and a range of other ailments.

The FTC alleged that Renaissance falsely claimed to have tests and studies to support its product claims. It also failed to disclose that the endorsers appearing in its Isoprex ads either were compensated for their testimonials or were company employees.

The court order settling the FTC’s complaint prohibits the defendants from making health claims unless they are true and supported by reliable tests or studies. The order also requires Renaissance to pay money to the FTC to provide the refunds.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Manatt, Phelps & Phillips, LLP | Attorney Advertising

Written by:

Manatt, Phelps & Phillips, LLP
Contact
more
less

Manatt, Phelps & Phillips, LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.